Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Logs Positive PII/III Results for TAK-881 in PID, Eyes FY2026 Filing
Takeda Pharmaceutical’s investigational immunoglobulin therapy TAK-881 met the primary endpoint in a global PII/III trial in patients with primary immunodeficiency disease (PID), demonstrating a pharmacokinetic comparability with HyQvia. The TAK-881-3001 study enrolled adults and children aged two years and older…
To read the full story
BUSINESS
- Daiichi Sankyo Cuts FY2025 Profit Outlook on ADC Supply Plan Review
May 11, 2026
- Capricor Sues Nippon Shinyaku over US Rights to DMD Cell Therapy
May 11, 2026
- FDA Delays Review of Leqembi Iqlik for Alzheimer’s Initiation Therapy
May 11, 2026
- Kyorin Begins Japan PIII Trial of Beova in Pediatric OAB
May 11, 2026
- Kyowa Kirin Keeps Long-Term KPIs despite OX40 Setback, Ups 2026 Core Profit Outlook
May 11, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…